Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZENFLEX Pro is a peripheral drug-eluting stent (DES) system developed by Zylox-Tonbridge Medical Technology. It is specifically designed for the treatment of peripheral artery disease (PAD) in the above-the-knee femoropopliteal arteries, including the superficial femoral artery and proximal popliteal artery. The device features a self-expanding nitinol stent platform coated with paclitaxel, an antiproliferative agent that inhibits smooth muscle cell migration and proliferation to prevent restenosis. ZENFLEX Pro utilizes a proprietary ultrasound spray crystalline coating technology to create a uniform and stable drug layer on the stent surface. The system received CE certification in October 2020, marking its approval for use in the European market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZENFLEX Pro.